bortezomib
E241388
antineoplastic agent
antineoplastic immunomodulating agent
chemotherapy drug
peptidyl boronic acid
proteasome inhibitor
small molecule drug
Bortezomib is a proteasome inhibitor chemotherapy drug primarily used in the treatment of multiple myeloma and certain types of lymphoma.
All labels observed (4)
| Label | Occurrences |
|---|---|
| Bortezomib Accord | 1 |
| Bortezomib Teva | 1 |
| Velcade | 1 |
| bortezomib canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T2190710 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: bortezomib Context triple: [Darzalex, usedInCombinationWith, bortezomib]
-
A.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
B.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
C.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
D.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
E.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: bortezomib Target entity description: Bortezomib is a proteasome inhibitor chemotherapy drug primarily used in the treatment of multiple myeloma and certain types of lymphoma.
-
A.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
B.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
C.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
D.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
E.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
- F. None of above. chosen
Statements (55)
| Predicate | Object |
|---|---|
| instanceOf |
antineoplastic agent
ⓘ
antineoplastic immunomodulating agent ⓘ chemotherapy drug ⓘ peptidyl boronic acid ⓘ proteasome inhibitor ⓘ small molecule drug ⓘ |
| adverseEffect |
anemia
ⓘ
constipation ⓘ diarrhea ⓘ fatigue ⓘ herpes zoster reactivation ⓘ nausea ⓘ neutropenia ⓘ peripheral neuropathy ⓘ thrombocytopenia ⓘ |
| developer |
Johnson & Johnson
ⓘ
Millennium Pharmaceuticals ⓘ |
| firstApprovalAgency |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
| firstApprovalYear | 2003 ⓘ |
| hasATCCode | L01XX32 ⓘ |
| hasBioavailability | 100% (intravenous) ⓘ |
| hasCASNumber | 179324-69-7 ⓘ |
| hasEffect |
disrupts protein homeostasis in cancer cells
ⓘ
induces apoptosis in malignant plasma cells ⓘ |
| hasEliminationHalfLife | approximately 9 to 15 hours ⓘ |
| hasMechanismOfAction |
inhibits chymotrypsin-like activity of the proteasome
ⓘ
reversible inhibitor of the 26S proteasome ⓘ |
| hasMolecularFormula | C19H25BN4O4 ⓘ |
| hasMolecularWeight | 384.24 g/mol ⓘ |
| hasTradeName |
Bortecad
ⓘ
bortezomib self-linksurface differs ⓘ
surface form:
Bortezomib Accord
bortezomib self-linksurface differs ⓘ
surface form:
Bortezomib Teva
bortezomib self-linksurface differs ⓘ
surface form:
Velcade
|
| indication |
mantle cell lymphoma
ⓘ
multiple myeloma ⓘ previously untreated mantle cell lymphoma ⓘ previously untreated multiple myeloma ineligible for transplant ⓘ relapsed multiple myeloma ⓘ |
| legalStatusEU | prescription only ⓘ |
| legalStatusUS | prescription only ⓘ |
| metabolism | primarily hepatic ⓘ |
| metabolizingEnzyme |
CYP1A2
ⓘ
CYP2C19 ⓘ CYP3A4 ⓘ |
| oftenUsedWith |
cyclophosphamide
ⓘ
dexamethasone ⓘ lenalidomide ⓘ cyclophosphamide ⓘ
surface form:
melphalan
prednisone ⓘ |
| pregnancyCategoryUS | D ⓘ |
| proteinBinding | high ⓘ |
| routeOfAdministration |
intravenous
ⓘ
subcutaneous ⓘ |
| target | 26S proteasome beta 5 subunit ⓘ |
| UNII | Q9Y238A5X4 ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: bortezomib Description of subject: Bortezomib is a proteasome inhibitor chemotherapy drug primarily used in the treatment of multiple myeloma and certain types of lymphoma.
Referenced by (4)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
Velcade
this entity surface form:
Bortezomib Accord
this entity surface form:
Bortezomib Teva